Literature DB >> 23077033

NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.

Ana Clara Cristóvão1, Subhrangshu Guhathakurta, Eugene Bok, Goun Je, Seung Don Yoo, Dong-Hee Choi, Yoon-Seong Kim.   

Abstract

Accumulation of misfolded α-synuclein is the pathological hallmark of Parkinson's disease (PD). Nevertheless, little is known about the mechanism contributing to α-synuclein aggregation and its further toxicity to dopaminergic neurons. Since oxidative stress can increase the expression and aggregation levels of α-synuclein, NADPH oxidases (Noxs), which are responsible for reactive oxygen species generation, could be major players in α-synucleinopathy. Previously, we demonstrated that Nox1 is expressed in dopaminergic neurons of the PD animal models as well as postmortem brain tissue of PD patients, and is responsible for oxidative stress and subsequent neuronal degeneration. Here, using paraquat (PQ)-based in vitro and in vivo PD models, we show that Nox1 has a crucial role in modulating the behavior of α-synuclein expression and aggregation in dopaminergic neurons. We observed in differentiated human dopaminergic cells that Nox1 and α-synuclein expressions are increased under PQ exposure. Nox1 knockdown significantly reduced both α-synuclein expression and aggregation, supporting the role of Nox1 in this process. Furthermore, in rats exposed to PQ, the selective knockdown of Nox1 in the substantia nigra, using adeno-associated virus encoding Nox1-specific shRNA, largely attenuated the PQ-mediated increase of α-synuclein and ubiquitin expression levels as well as α-synuclein aggregates (proteinase K resistant) and A11 oligomers. Significant reductions in oxidative stress level and dopaminergic neuronal loss were also observed. Our data reveal a new mechanism by which α-synuclein becomes a neuropathologic protein through Nox1-mediated oxidative stress. This finding may be used to generate new therapeutic interventions that slower the rate of α-synuclein aggregation and the progression of PD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23077033      PMCID: PMC3501265          DOI: 10.1523/JNEUROSCI.2246-12.2012

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  44 in total

1.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Authors:  Scott Q Harper; Patrick D Staber; Xiaohua He; Steven L Eliason; Inês H Martins; Qinwen Mao; Linda Yang; Robert M Kotin; Henry L Paulson; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

2.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro.

Authors:  M Hashimoto; L J Hsu; Y Xia; A Takeda; A Sisk; M Sundsmo; E Masliah
Journal:  Neuroreport       Date:  1999-03-17       Impact factor: 1.837

4.  Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death.

Authors:  Dong-Hee Choi; Youn-Jung Kim; Young-Gun Kim; Tong H Joh; M Flint Beal; Yoon-Seong Kim
Journal:  J Biol Chem       Date:  2011-02-17       Impact factor: 5.157

5.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

Review 6.  Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins.

Authors:  D A Butterfield; J Kanski
Journal:  Mech Ageing Dev       Date:  2001-07-15       Impact factor: 5.432

7.  The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein.

Authors:  Amy B Manning-Bog; Alison L McCormack; Jie Li; Vladimir N Uversky; Anthony L Fink; Donato A Di Monte
Journal:  J Biol Chem       Date:  2001-11-13       Impact factor: 5.157

8.  Kinetics of peroxynitrite reaction with amino acids and human serum albumin.

Authors:  B Alvarez; G Ferrer-Sueta; B A Freeman; R Radi
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157

Review 9.  The genetics of Parkinson's syndromes: a critical review.

Authors:  John Hardy; Patrick Lewis; Tamas Revesz; Andrew Lees; Coro Paisan-Ruiz
Journal:  Curr Opin Genet Dev       Date:  2009-05-04       Impact factor: 5.578

10.  alpha-Synuclein and neuronal cell death.

Authors:  Mark R Cookson
Journal:  Mol Neurodegener       Date:  2009-02-04       Impact factor: 14.195

View more
  43 in total

Review 1.  New insights on NOX enzymes in the central nervous system.

Authors:  Zeynab Nayernia; Vincent Jaquet; Karl-Heinz Krause
Journal:  Antioxid Redox Signal       Date:  2014-01-16       Impact factor: 8.401

Review 2.  Therapeutic potential of NADPH oxidase 1/4 inhibitors.

Authors:  G Teixeira; C Szyndralewiez; S Molango; S Carnesecchi; F Heitz; P Wiesel; J M Wood
Journal:  Br J Pharmacol       Date:  2016-07-14       Impact factor: 8.739

Review 3.  Deregulation of α-synuclein in Parkinson's disease: Insight from epigenetic structure and transcriptional regulation of SNCA.

Authors:  Subhrangshu Guhathakurta; Eugene Bok; Baggio A Evangelista; Yoon-Seong Kim
Journal:  Prog Neurobiol       Date:  2017-04-23       Impact factor: 11.685

Review 4.  Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs.

Authors:  Delphine Charvin; Rossella Medori; Robert A Hauser; Olivier Rascol
Journal:  Nat Rev Drug Discov       Date:  2018-09-28       Impact factor: 84.694

Review 5.  Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery.

Authors:  Maykel Cruz-Monteagudo; Stephan Schürer; Eduardo Tejera; Yunierkis Pérez-Castillo; José L Medina-Franco; Aminael Sánchez-Rodríguez; Fernanda Borges
Journal:  Drug Discov Today       Date:  2017-03-06       Impact factor: 7.851

Review 6.  Antioxidant gene therapy against neuronal cell death.

Authors:  Juliana Navarro-Yepes; Laura Zavala-Flores; Annadurai Anandhan; Fang Wang; Maciej Skotak; Namas Chandra; Ming Li; Aglaia Pappa; Daniel Martinez-Fong; Luz Maria Del Razo; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Pharmacol Ther       Date:  2013-12-12       Impact factor: 12.310

7.  PKCδ mediates paraquat-induced Nox1 expression in dopaminergic neurons.

Authors:  Ana Clara Cristóvão; Joana Barata; Goun Je; Yoon-Seong Kim
Journal:  Biochem Biophys Res Commun       Date:  2013-07-02       Impact factor: 3.575

8.  Mito-Apocynin Prevents Mitochondrial Dysfunction, Microglial Activation, Oxidative Damage, and Progressive Neurodegeneration in MitoPark Transgenic Mice.

Authors:  Monica Langley; Anamitra Ghosh; Adhithiya Charli; Souvarish Sarkar; Muhammet Ay; Jie Luo; Jacek Zielonka; Timothy Brenza; Brian Bennett; Huajun Jin; Shivani Ghaisas; Benjamin Schlichtmann; Dongsuk Kim; Vellareddy Anantharam; Arthi Kanthasamy; Balaji Narasimhan; Balaraman Kalyanaraman; Anumantha G Kanthasamy
Journal:  Antioxid Redox Signal       Date:  2017-04-04       Impact factor: 8.401

Review 9.  NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Authors:  Becky A Diebold; Susan M E Smith; Yang Li; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

Review 10.  Elucidating Critical Proteinopathic Mechanisms and Potential Drug Targets in Neurodegeneration.

Authors:  Khalid Bashir Dar; Aashiq Hussain Bhat; Shajrul Amin; Bilal Ahmad Reshi; Mohammad Afzal Zargar; Akbar Masood; Showkat Ahmad Ganie
Journal:  Cell Mol Neurobiol       Date:  2019-10-04       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.